Correlation between Treatment Outcomes and Serum Vitamin D Levels As Well As Infliximab Trough Concentration among Chinese Patients with Crohn’s Disease

Table 2

Biochemical parameters, nutritional indices, and clinical assessment at three follow-up time points.

Time point

Vit-D status

Biochemical parameters

CDAI

SES-CD

Biochemical remission

Clinical remission

Endoscopic remission

Endoscopic response

Inflammatory indices IQR/N

Nutritional indices

Enrollment

IQR/N 16.15 (9.55~21.875)/84

CRP

22.1 (5~61.3)/84

Hb

114.5 (92.3~127.5)/84

136.5 (101.25~196)/84

13 (5~23)/84

/

/

/

/

Sufficiency, (%)

7/84 (8.3)

hs-CRP

27.2 (6.5~62.3)/84

PA

157 (116~212.8)/84

Insufficiency, (%)

23/84 (27.4)

ESR

22 (12.25~40)/84

ALB

38.9 (35.8~43.9)/84

Deficiency, (%)

54/84 (64.3)

PLT

382.5 (300.8~461.8)/84

/

Week 14

IQR/N 21.8 (16.95~25.65)/60

CRP

5 (3.1~5)/59

Hb

142 (133~151)/65

137.5 (114~166.5)/76

/

48/60 (80)

53/76 (69.7)

/

/

Sufficiency, (%)

7/60 (11.67)

hs-CRP

0.99 (0.4~5.3)/65

PA

259 (216~298)/63

Insufficiency, (%)

28/60 (46.7)

ESR

5 (3~10.5)/65

ALB

48.3 (44.5~50.9)/65

Deficiency, (%)

25/60 (41.67)

PLT

246 (213.5~287)/65

/

Week 38

IQR/N 21.1 (16.2~27.7)/47

CRP

5 (3.7~6.6)/47

Hb

144 (126.5~152.25)/50

120 (93~142.75)/52

2 (0~4)/58

35/46 (76.1)

46/52 (88.5)

13/58 (22.4)

39/58 (67.2)

Sufficiency, (%)

9/47 (19.12)

hs-CRP

1.84 (0.4~8.1)/49

PA

250 (219.75~297.5)/50

Insufficiency, (%)

20/47 (42.55)

ESR

5.6 (3~12)/49

ALB

46.6 (45.1~50.0)/50

Deficiency, (%)

18/47 (38.3)

PLT

260 (209.3~308.3)/50

/

Vit-D: vitamin D; CDAI: Crohn’s disease activity index; SES-CD: simplified endoscopic activity score for Crohn’s disease; IFX: infliximab; IQR: interquartile range; CRP: C-reactive protein; hs-CRP: high-sensitive C-reaction protein; ESR: erythrocyte sedimentation rate; PTL: platelet; Hb: hemoglobin; PA: prealbumin; ALB: albumin. Week 14 vs. enrollment vs. enrollment. ; .